We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Gene Technology Grants Microarray License to Applied Microarray Inc.
News

Oxford Gene Technology Grants Microarray License to Applied Microarray Inc.

Oxford Gene Technology Grants Microarray License to Applied Microarray Inc.
News

Oxford Gene Technology Grants Microarray License to Applied Microarray Inc.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Gene Technology Grants Microarray License to Applied Microarray Inc."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT) and Applied Microarrays Inc (AMI) have announced the completion of a licence agreement granting AMI access to OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.

Applied Microarrays Inc., who recently acquired Codelink technology from GE Healthcare, are  now  licensed to fabricate, market and distribute Codelink microarrays worldwide.

In addition, this license grants OEM rights allowing AMI to manufacture custom microarrays for third parties under their own brand name. All microarrays fabricated by AMI include rights for their use within Service organisations.

Sue Sutton, Vice President Licensing North America, at OGT said: “This license agreement is important in that it will ensure the continued supply of Codelink microarrays to the market and gives companies without their own microarray fabrication facility the opportunity to add microarrays to their product portfolio”.

The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.

Advertisement